CTIS2024-515384-62-00招募中1 期
Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized Soft Tissue Sarcoma - 19SARC05
Oncopole Claudius Regaud0 个研究点目标入组 600 人开始时间: 2024年6月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Diagnosis of soft-tissue sarcoma, histologically confirmed by RRePS (Réseau de Référence en Pathologie des Sarcomes et des Viscères) network, 10.Signed written informed consent, 11.Patient affiliated to a Social Health Insurance in France, 1.High-risk CINSARC signature (FOR THE RANDOMIZED PHASE III STUDY), 2.Acceptable hematologic function (within 72 hours prior randomization): Absolute neutrophil count (ANC) = 1.5 G/L, Platelet count = 100 G/L and Hemoglobin > 9g/dL, 3.Acceptable renal function within 72 hours prior randomization: Serum creatinine = 1.5 x ULN or calculated creatinine clearance = 60 mL/min (by the Cockcroft and Gault formula), 4.Acceptable liver function: Bilirubin = 1.5 x upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) = 2.5 x ULN, 5.Normal LVEF (>50%) measured by echocardiography or isotopic ventriculography, 2.According to FNCLCC grading system, grade 1, 2 or 3 tumors, 2.According to FNCLCC grading system, grade 1, 2 or 3 tumors 3.Resectable and localized disease after appropriate extension work-up (including at least a chest-CT), 4.6 weeks or less between surgical excision and inclusion (if performed before inclusion), 5.Available archived FFPE tumor sample in sufficient quantity to allow CINSARC qualification, 6.Age = 18 years, 7.Eastern Cooperative Oncology Group (ECOG) performance status = 2, 8.Life expectancy of at least 12 weeks after the start of the treatment, 9.Women should be post-menopaused or willing to accept the use an effective contraceptive regimen during the treatment period and at least 12 months after the end of the treatment period. All non-menopaused women should have a negative pregnancy test within 72 hours prior to registration
排除标准
- •1.Soft-tissue sarcoma with the following histological subtypes: welldifferentiated liposarcomas, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, epithelioid sarcoma, alveolar or embryonal rhabdomyosarcoma, 10.Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy, 11.Known infection with HIV, hepatitis B, or hepatitis C, 12.Women who are breastfeeding, pregnant or who plan to become pregnant while in the trial, 13.Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study, 14.Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice), 15.Patient unable to comply with the protocol for any reason, 2.Primitive cutaneous, retroperitoneal, uterus or visceral STS, 3.Metastatic disease, 4.Previous or ongoing treatment for the sarcoma (with the exception of surgical excision), 5.Contra-indication for Doxorubicin, Ifosfamide and Dacarbazine treatments, 6.Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards, and prior therapy with anthracyclines, 7.Prior mediastinal/cardiac radiotherapy, 8.History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia, myocardial infarction within 6 months prior to study entry, 9.Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma
研究者
相似试验
进行中（未招募）
1 期
Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma.Soft Tissue SarcomaMedDRA version: 20.0Level: PTClassification code 10075333Term: Soft tissue sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-003014-13-FRINSTITUT CLAUDIUS REGAUD600
招募中
2 期
The efficacy and safety of perioperative chemotherapy for locally advanced colorectal cancer. - The phase II studylocally advanced colorectal cancerJPRN-UMIN000024323Kansai Medical University Medical Center35
招募中
2 期
Perioperative chemotherapy for locally advanced colorectal cancer.locally advanced colon cancerJPRN-jRCTs051180167Tokuhara Katsuji35
招募中
不适用
Feasibility study of perioperative chemotherapy with neoadjuvant GEM+CDDP and adjuvant S-1 for biliary tract cancerBiliary tract cancerJPRN-UMIN000021206Keio University School of Medicine30
招募中
2 期
Phase II study of perioperative chemotherapy (preoperative XELOX+Bevacizumab/ postoperative XELOX) in patients with locally advanced rectal cancerRectal cancerJPRN-UMIN000013000Sano Hospital Masahito Kotaka, MD50